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Abstract
Introduction Liver transplantation has emerged as a successful therapy for end-stage liver disease. However, cardiovascular
mortality is the leading cause of fatality in the postoperative period. The aim of this study was to reveal the prevalence
and identify risk factors of early cardiovascular events (CVEs).
Methods We performed a retrospective study of all consecutive patients who underwent a primary liver transplantation
from 1986 to 2017 (n= 916). We investigated the occurrence of in-hospital CVEs, their predictors, and short- and long-term
outcome.
Results The prevalence of CVEs was 11%. The adjusted analysis showed that higher age (OR 1.06, 95% CI 1.03–1.09),
higher MELD score (OR 1.04, 95% CI 1.01–1.07 CI) and sinus tachycardia at time of screening (OR 3.12, 95% CI
1.45–6.72) were positive predictors for a CVE. Preoperative propranolol use showed a trend towards a higher risk of
CVE (OR 1.66, 95% CI 1.00–2.77, p= 0.051). In a sub-analysis of patients where echocardiography data were available
(n= 597), a larger left atrial diameter and a higher E/E0 ratio were related to early CVEs. Ten-year survival in 30-day
survivors was favourable (68.6%; 56.0% vs. 69.8% in the CVE+ vs. the CVE-group, respectively, p= 0.056).
Discussion In conclusion, besides known risk factors (age and MELD score), sinus tachycardia (related to the presence
of acute liver failure and cirrhosis) was an independent predictor for CVE after liver transplantation.
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What’s new
● This is an observational study on predictors of in-hospital
cardiovascular events (CVEs) after liver transplantation
(LT).
● The risk of CVEs after LT was associated with preoper-
ative sinus tachycardia (related to the presence of acute
liver failure and cirrhosis, no interaction with the use of
propranolol), age and MELD score.
● CVEs were more likely in patients with a larger left atrial
diameter and higher E/E0, as indirect indicators for left
atrial pressure and diastolic dysfunction.
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● Preoperative propranolol use at least did not protect
against the risk of CVE.
● The occurrence of CVEs in 30-day survivors did not sig-
nificantly impair long-term outcome.
Introduction
Liver transplantation is the treatment for end-stage liver
disease. Patients who undergo liver transplantation are at
risk for early postoperative cardiovascular events (CVE),
primarily through physical stress due to baseline altered
haemodynamics as well as perioperative cytokine release
and further haemodynamic instability [1–3]. Whereas car-
diovascular mortality is the leading cause of short-term
death, data on early postoperative cardiovascular events and
how these impact long-term outcome are scarce [4]. In pre-
vious studies, the prevalence of CVE was estimated to be
12% at 30 days [5, 6]. Occurrence of an early CVE may
impact long-term survival [6, 7]. Identification of predictors
for early CVEs may impact patient selection and periopera-
tive management. The aims of this study were to investigate
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the occurrence of early CVEs, to find predictors identified
at the time of screening and to describe the correlation with
long-term survival.
Methods
We performed a retrospective study in 923 consecutive pa-
tients subjected to their first liver transplant at the Erasmus
MC, Rotterdam, the Netherlands between October 1986 and
January 2017. All candidates for transplantation received
a cardiac evaluation, which at least included a complete his-
tory, physical examination and electrocardiogram (ECG). In
most cases, except in those who had acute liver failure and
underwent highly urgent transplantation, also echocardiog-
raphy was performed. If indicated by the screening cardi-
ologist, additional tests were carried out.
All data were extracted from the existing liver trans-
plantation database, and (if needed) completed with data
from the patient record. The database consisted of the fol-
lowing variables: age, gender, history of hypertension, cur-
rent smoking, diabetes mellitus, dyslipidaemia, cardiovas-
cular history (arrhythmias, valve disease, cardiomyopathy
including heart failure, ischaemic heart disease and cere-
brovascular accident or transient ischaemic accident), renal
impairment (glomerular filtration rate <60, calculated with
MDRD), Model of End-stage Liver Disease (MELD) score,
and preoperative propranolol use. ECG data were used to
assess heart rate and arrhythmias, including sinus tachycar-
dia, and left ventricular hypertrophy. All baseline variables
were identified at the time of screening for liver transplan-
tation, except the MELD score, renal impairment and body
mass index (BMI), which were calculated at the time of
transplantation. Echocardiography data were collected in
order to reveal left ventricular dimensions, systolic func-
tion, diastolic function, valve disease and pericardial effu-
sion. ECG and echocardiography data were authorised by
staff cardiologists without involvement in this research. In
case of uncertainties the primary investigator (CU) reviewed
the echocardiographic images blinded for outcomes.
The primary endpoint was the occurrence of in-hospi-
tal CVEs. CVEs were defined as myocardial infarction, de
novo heart failure, arrhythmias (de novo atrial fibrillation or
postoperative recurrent supraventricular tachycardia, other
ventricular and supraventricular arrhythmias, or bradycar-
dia), cardiopulmonary resuscitation (including pulseless
ventricular tachycardia/fibrillation), stroke, or pulmonary
embolism, all occurring after transplantation but within the
early postoperative period. The early postoperative period
was defined as the in-hospital period following transplanta-
tion where, for patients who had a hospitalisation duration
longer than 30 days, only CVEs occurring within 30 days
were included. Results were stratified according to the
occurrence of CVE. The secondary endpoint was survival
in the short (30 days) and long term. In January 2017,
patient survival status was extracted from the Municipal
Civil Registries.
Continuous variables are expressed as means with stan-
dard deviation (±SD) or median with interquartile range
(IQR). Categorical variables are presented as numbers with
percentages. Continuous variables are analysed with the un-
paired Student’s t-test if normally distributed or the Mann-
Whitney U test otherwise. Normality was assessed using
the Shapiro-Wilk test. Categorical variables are compared
using the Chi-squire test or Fisher’s exact test when appro-
priate. All baseline variables are screened for an individual
association with CVE by univariate binary logistic regres-
sion. In addition to age and gender, the multivariate binary
logistic regression analysis included all baseline character-
istics that indicated a difference between the two groups (p-
value 0.10). The outcomes are presented as adjusted odds
ratios (ORs) with 95% confidence interval (CI). Thirty-day
and long-term survival was studied using the Kaplan-Meier
method, with the log-rank test to evaluate differences be-
tween the CVE+ group and the CVE-group. Patients lost
to follow-up were considered at risk until their last contact,
at which time point they were censored. A Cox-regression
model was used in order to adjust for age in long-term
survival. To take into account missing values (variables:
sinus tachycardia and MELD score), we also performed
a sensitivity analysis using multiple imputation to deter-
mine outcome differences between the original and the im-
puted dataset. Results were assumed statistically significant
if p< 0.05. All data were analysed with SPSS 20.0 software.
This was an observational study. For this study patients
were not subjected to any procedures, neither was any mode
of behaviour imposed, otherwise than as part of their regular
treatment. Therefore, according to Dutch law and by per-
mission of the local medical ethical committee, (repeated)
written informed consent for a patient to be enrolled in this
study was not required. Besides, all patients signed con-
sent for the collection and use of data as part of a routine
procedure to investigate outcomes of transplantation.
Results
In this study, data from 916 out of 923 patients who un-
derwent liver transplantation were used: 7 patients were
excluded due to incomplete data. Indications for transplan-
tation were cholestatic liver disease (35%), cirrhosis (25%),
hepatocellular carcinoma (18%), acute liver failure (14%)
and other less common liver diseases (10%). During screen-
ing, 597 (65.2%) patients underwent echocardiography. In
total 167 (18%) patients underwent additional testing: 18
(2%) had right heart catheterisation, 47 (5%) had an exer-
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Table 1 Baseline characteristics
All patients CVE+ CVE– Missing p-value
(n= 916) (n= 100) (n= 816)
Age, years, mean± SD 48.8± 12.5 54.2± 10.7 48.2± 12.5 <0.001
Male sex, n (%) 552 (60.3) 65 (65.0) 487 (59.7) 0.31
Cardiovascular risk factors
History of hypertension, n (%) 143 (15.6) 24 (24.0) 119 (14.6) 0.014
Current smoking, n (%) 172 (23.2) 16 (20.0) 156 (23.6) 176 0.47
Dyslipidaemia, n (%) 53 (6.3) 6 (5.9) 47 (6.3) 70 0.87
Diabetes mellitus, n (%) 143 (15.6) 22 (22.0) 121 (14.8) 0.062
History of cardiovascular disease, n (%) 80 (8.7) 13 (13.0) 67 (8.2) 0.11
Ischaemic heart disease 15 (1.6) 4 (4.0) 11 (1.3) 0.071
Cardiomyopathy 4 (0.4) 0 (0) 4 (0.5) 1.00
Valve disease 10 (1.2) 0 (0) 10 (1.1) 0.61
Arrhythmias 35 (3.8) 6 (6.0) 29 (3.6) 0.23
CVA or TIA 5 (0.5) 1 (1.0) 4 (0.5) 0.44
Othera 5 (0.5) 2 (2.0) 3 (0.4) 0.10
Renal impairment, n (%)b 205 (22.4) 36 (36.0) 169 (20.8) 2 0.001
BMI (kg/m2; mean± SD) 25.3± 4.3 26.2± 4.5 25.2± 4.3 6 0.033
Angina pectoris n (%) 14 (1.6) 1 (1.0) 13 (1.6) 17 1.00
Electrocardiography, n (%)
Sinus tachycardia 53 (5.8) 12 (12.0) 41 (5.0) 77 0.005
Left ventricular hypertrophy 73 (9.4) 7 (8.2) 66 (9.5) 136 0.71
Arrhythmias or AV-block 29 (3.2) 6 (6.0) 23 (2.8) 0.086
Atrial fibrillation 14 (1.5) 4 (4.0) 10 (1.2) 0.057
First degree AV-block 11 (1.2) 1 (1.0) 10 (1.2) 1.00
Otherc 4 (0.4) 1 (1.0) 3 (0.4) 0.37
Pathological Q-wave, n (%) 1 (0.1) 1 (1.0) 0 (0) 0.11
MELD score at time of transplant, median (IQR) 18 (13–25) 20 (15–28) 17 (13–24) 40 0.007
Propranolol use, n (%) 205 (22.4) 29 (29.0) 176 (21.6) 0.092
Aetiology of liver disease, n (%)
Acute liver failure 127 (13.9) 18 (18.0) 109 (13.4) 0.21
NASH 16 (1.7) 1 (1.0) 15 (1.8) 1.00
BMI body mass index; CVA cerebrovascular accident; CVE cardiovascular event; MELD score Model for end-stage liver disease;
NASH non-alcoholic steatosis hepatitis; TIA transient ischaemic accident
aPericarditis, congenital heart disease and aortic aneurysmatic disease
bRenal impairment: MDRD, eGFR <60ml/min/1.73m2
cParoxysmal atrial tachycardia (n= 1), paced rhythm (n= 1), atrial rhythm (n= 2)
cise test, 90 (10%) had dobutamine stress echocardiography,
2 (0.2%) had contrast echocardiography, 9 (1%) had a Tc-
MIBI scan, 7 (0.8%) underwent Holter ECG monitoring,
and 4 (0.4%) underwent coronary angiography. Reasons
for these additional tests were angina pectoris or palpita-
tions (11%), exercise tolerance unclear from the history
(0.6%), a history of cardiovascular disease or cardiovas-
cular risk factors (30%), ECG or echocardiography abnor-
malities (13%), other research purposes not related to the
current study (35%), or unknown. The additional tests iden-
tified 3 patients with mild pulmonary hypertension (mean
pulmonary artery pressures 25–30mmHg) and 2 patients
with coronary ischaemia who were managed medically.
Of 916 patients, 100 (11%) experienced a CVE. Iden-
tified CVEs were: myocardial infarction (13%), heart fail-
ure (3%), arrhythmias (34%), cardiopulmonary resuscita-
tion (28%), stroke (9%), venous thromboembolism (11%),
pericardial tamponade (1%) and hypertensive crisis (1%).
Baseline characteristics are presented in Tab. 1. Patients
with a CVE event were older (54± 11 vs. 48± 13, p< 0.001),
more frequently had hypertension (24% vs. 15%, p= 0.01),
had more renal failure (36% vs. 21%, p= 0.001), and had
a higher BMI (26± 5 vs. 25± 4, p= 0.03). In addition,
sinus tachycardia was more frequently present (12% vs.
5%, p= 0.005) and the MELD score (20 [15–28] vs. 17
[13–24], p= 0.007) was higher. Only 1 patient with preoper-
ative atrial fibrillation and 1 patient with paroxysmal atrial
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Table 2 Echocardiography data
All patients CVE+ CVE– Missing p-value
(n= 597) (n= 64) (n= 533)
Estimated systolic PA pressure (mm Hg; mean± SD) 27.7± 8.2 27.3± 9.8 27.8± 8.0 311 0.76
Left ventricular function, n (%) 7 0.10
Good 564 (95.4) 65 (91.5) 499 (96.0)
Moderate 27 (4.6) 6 (8.5) 21 (4.0)
Interventricular septum (mm; mean± SD) 9.5± 2.1 9.9± 2.8 9.4± 2.0 209 0.25
Posterior wall thickness (mm; mean± SD) 8.9± 1.6 9.3± 1.6 8.9± 1.6 216 0.12
Left ventricular end-diastolic diameter (mm; mean± SD) 49.8± 6.9 49.7± 6.3 49.8± 6.9 208 0.96
LV mass (g; mean± SD) 164± 54 172± 47 163± 54 219 0.33
Left atrial diameter (mm; mean± SD) 41.5± 6.4 43.7± 5.2 41.2± 6.5 198 0.02
E/A ratio (mean± SD) 1.3± 0.4 1.2± 0.5 1.3± 0.4 186 0.93
E/E0 ratio (mean± SD) 9.9± 3.1 11.1± 3.1 9.8± 3.1 254 0.02
Valve disease, n (%) 3
Aortic insufficiency 4 (0.7) 2 (2.8) 2 (0.4) 0.07
Aortic stenosis 2 (0.3) 0 (0) 2 (0.4) 1.00
Mitral insufficiency 9 (1.5) 2 (2.8) 7 (1.3) 0.30
Tricuspid insufficiency 8 (1.3) 1 (1.4) 7 (1.3) 1.00
Pericardial effusion, n (%) 13 (2.6) 1 (1.8) 12 (2.7) 103 1.00
tachycardia had a postoperative event of supraventricular
tachycardia. The patient who had a pacemaker did not have
a CVE. Sinus tachycardia was often present in patients with
acute liver failure (45.3%) and in patients with cirrhosis
(30.2%). The 5 patients who underwent additional testing
did not have a cardiovascular event after liver transplant.
Echocardiography data (available in n= 597, 65%) are
presented in Tab. 2. Patients with a cardiovascular event had
a larger left atrial (LA) diameter (44± 5 vs. 41± 7, p= 0.02)
and a greater E/E0 ratio (11± 3 vs. 10± 3, p= 0.02). Patients
with cirrhosis had a significantly higher preoperative E/E0
ratio (11± 3 vs. 10± 3, p< 0.001) and LA diameter (43± 6
vs. 41± 7, p< 0.001). There was no relation between LA
diameter or E/E0 and the presence of sinus tachycardia.
Fig. 1 Univariate analysis. MELD score Model for End-stage Liver
Disease
The results of univariate analysis are presented in Fig. 1.
In multivariate analysis, we found that a higher age (OR
1.06, 95% CI 1.03–1.09), higher MELD score (OR 1.04,
95% CI 1.01–1.07 CI) and sinus tachycardia (OR 3.12,
95% CI 1.45–6.72) were positive predictors for a CVE
(Fig. 2). Propranolol use (administered for the treatment of
cirrhotic portal hypertension and/or oesophageal varices)
showed a trend towards significance (OR 1.66, 95% CI
1.00–2.77, p= 0.051). The following interaction terms
were calculated and found not significant: propranolol
use—sinus tachycardia, propranolol use—MELD score,
propranolol use—postoperative atrial fibrillation, and pro-
pranolol use—hypertension. After imputing missing values
and repeating the analysis mentioned above, no differences
were observed. Hence, we present the original data.
Within the first 30 days after liver transplant, there was
a lower survival rate (74% vs. 95%, log rank <0.001) in the
CVE+ versus the CVE– group, respectively. There was no
difference in overall 30-day survival in patients with sinus
tachycardia compared with those without sinus tachycardia.
Median follow-up time in 30-day survivors was 4.9 years
(IQR: 1.3–10.0 years). At 10 years, 209 patients of 30-day
survivors (31%) had died. Patients with a cardiovascular
event (CVE+) did not have a significantly lower survival
rate (log rank= 0.06) at 10 years compared with the CVE–
group (Fig. 3). Long-term survival adjusted for age was not
different between the two groups (p= 0.21).
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Fig. 2 Multivariate analysis. MELD score Model for End-stage Liver
Disease
Fig. 3 30-day survival and long-term survival. CVE Cardiovascular
event
Discussion
This study aimed to identify predictors of early CVEs
after liver transplantation and the association with short-
and long-term outcome. Our main finding was that the
risk of a CVE after transplant was associated with sinus
tachycardia (without obvious interaction with the use of
propranolol), age and MELD score. In a subgroup of pa-
tients, LA diameter and E/E0 were related to CVE. The
occurrence of CVE did not significantly impact long-term
mortality in 30-day survivors.
The presence of sinus tachycardia was an independent
predictor for CVE. In the literature, we found no previ-
ous evidence for the association between sinus tachycardia
and CVE after liver transplantation. A possible explanation
might be that patients with sinus tachycardia frequently had
acute liver failure (45.3%). Acute liver failure causes va-
sodilatation, low vascular resistance and hypotension, with
a compensatory increase of heart rate [8]. In addition, pa-
tients with acute liver failure may have a higher periopera-
tive mortality in comparison with more chronic indications
for liver transplant [9], although this was not confirmed
by our data. Another explanation might be that the pres-
ence of sinus tachycardia preferentially selected patients
with cirrhosis (30.2%). Some patients with cirrhosis may
have cirrhotic cardiomyopathy, characterised by diastolic
dysfunction (as confirmed by our data), which may cause
sinus tachycardia in the compensatory phase [10]. A post-
operative increase in peripheral vascular resistance, together
with changes in preload may precipitate perioperative and
postoperative heart failure [11]. Other confounding factors
such as thyroid disorders were not assessed in this study.
In line with previous studies, older patients were more
likely to experience a CVE [7, 12, 13]. Additionally, we
found that a higher MELD score was associated with
a CVE, which is also in agreement with a previous study
[14].
Preoperative use of propranolol tended to independently
predict CVE, in contrast to reports by others [5, 15]. Beta-
blocker use in general may be associated with postopera-
tive adverse outcome in patients undergoing major surgery
[16]. Second, patients who use propranolol are patients with
cirrhosis and, as indicated above, these patients may have
cirrhotic cardiomyopathy and diastolic dysfunction [17].
A previous study showed that diastolic dysfunction is as-
sociated with early heart failure after liver transplantation
[18].
Some variables did not predict CVE. First, renal im-
pairment showed predictive value in univariate analysis but
not in multivariate analysis. This finding is in contrast with
another study which suggested that patients with renal im-
pairment have an independent risk of CVEs [19]. Also, non-
alcoholic steatosis hepatitis was not associated with CVE,
which contradicts a previous study [20]. Finally, Dare et al.
suggested that BMI could be a risk factor for having CVEs
post liver transplant [21]. This finding could not be repro-
duced either.
In the current study, 10-year survival analysis revealed
a slightly higher mortality rate in 30-day survivors in the
CVE+ group, although not statistically significant. A larger
multicentre study showed a significantly higher mortality
rate in the event group [7]; however, we excluded patients
who died within the first 30 days.
The major limitation of this study was its retrospec-
tive nature, which accounts for the missing data. Missing
echocardiographic data are explained by the fact that the
transplantation was performed in a highly urgent (ICU) set-
ting, or patients were screened in another university hospital
and echocardiographic images/full reports were not sent to
our hospital, or echocardiographic data were lost over time.
Due to missing data, echocardiographic parameters could
not be entered into the multivariate analysis. A further lim-
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itation is that the ECG represented a snapshot, where no
routine supine resting period was standardised and longer
recordings were not routinely performed. Finally, LA di-
ameter was obtained to estimate LA size, where volumes
were not routinely measured.
This study presents risk factors and long-term outcome
in patients who experience a CVE after liver transplanta-
tion. Besides known risk factors (age and MELD score),
we identified other less obvious risk factors (sinus tachy-
cardia and maybe the use of propranolol) for the occur-
rence of CVE. In addition, CVE was more likely in patients
with a larger LA diameter and higher E/E0 as indirect in-
dicators for LA pressure and diastolic dysfunction. Long-
term survival was not significantly worse in patients who
survived an early CVE. Cardiologists should be aware of
the higher postoperative risk in a patient with preoperative
sinus tachycardia. The obvious suggestion from these data
to administer beta-blockers to lower CVE risk is clearly
not justified by our data. It might be of value to better in-
vestigate markers of diastolic dysfunction at the time of
screening to identify higher risk patients. How these find-
ings should change management strategies will be the topic
of further research.
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